Safety of secukinumab in the treatment of psoriasis

Expert Opinion on Drug Safety

Volumn 15, Issue 10, 2016, Pages 1413-1420

  Blauvelt, Andrew ^a  

^a OREGON MEDICAL RESEARCH CENTER   (United States)

Author keywords

Interleukin 17A; psoriasis; safety; secukinumab

Indexed keywords

ETANERCEPT; METHOTREXATE; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; DERMATOLOGICAL AGENT; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ANUS FISTULA; ARTHRALGIA; ARTICLE; BACKACHE; BENIGN TUMOR; BRAIN HEMORRHAGE; CANDIDIASIS; COMORBIDITY; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEART INFARCTION; HEPATITIS B; HERPES SIMPLEX; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LEUKEMIA; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MUCOCUTANEOUS CANDIDIASIS; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NON MELANOMA SKIN CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SCLEROSING CHOLANGITIS; SKIN DISEASE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; INTERLEUKIN-17; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84983372427     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1221923     Document Type: Article

References (37)

1. F.O.Nestle, D.H.Kaplan, J.Barker Psoriasis. N Engl J Med. 2009;361:496–509.
2. M.A.Lowes, M.Suárez-Fariñas, J.G.Krueger. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
3. A.S.Lønnberg, C.Zachariae, L.Skov. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–259.
4. J.G.Krueger, S.Fretzin, M.Suárez-Fariñas, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–154.
5. K.A.Papp, C.Leonardi, A.Menter, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
6. K.A.Papp, C.Reid, P.Foley, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis:results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132:2466–2469.
7. W.Hueber, D.D.Patel, T.Dryja, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
8. K.A.Papp, R.G.Langley, B.Sigurgeirsson, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis:a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412–421.
9. P.Rich, B.Sigurgeirsson, D.Thaci, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis:a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
10. R.G.Langley, B.E.Elewski, M.Lebwohl, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–338.• Pivotal study in the drug development program.
11. A.Blauvelt, J.C.Prinz, A.B.Gottlieb, et al. Secukinumab administration by pre-filled syringe:efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–493.
12. C.Paul, J.P.Lacour, L.Tedremets, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis:a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–1090.
13. D.Thaçi, A.Blauvelt, K.Reich, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis:CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.
14. D.Thaci, J.Humeniuk, Y.Frambach, et al. Secukinumab in psoriasis:randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777–787.
15. P.C.van de Kerkhof, C.E.Griffiths, K.Reich, et al. Secukinumab long-term safety experience:a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(83–98):e4.•• Pooled safety analysis of phase II and phase III clinical studies in psoriasis.
16. S.L.Gaffen, R.Jain, A.V.Garg, et al. The IL-23-IL-17 immune axis:from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585–600.
17. D.D.Patel, D.M.Lee, F.Kolbinger, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii116–123.
18. A.Blauvelt, M.G.Lebwohl, R.Bissonnette. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135:1946–1953.
19. S.Kagami, H.L.Rizzo, S.E.Kurtz, et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185:5453–5462.
20. C.E.Delsing, C.P.Bleeker-Rovers, F.L.van de Veerdonk, et al. Association of esophageal candidiasis and squamous cell carcinoma. Med Mycol Case Rep. 2012;1:5–8.
21. ClinicalTrials.gov. AIN457 regimen finding extension study in patients with moderate to severe psoriasis. [cited 2016 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT01132612.
22. U.Mrowietz, C.L.Leonardi, G.Girolomoni, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis:a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(27–36):e1.
23. K.Reich, K.A.Papp, R.T.Matheson, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24:529–535.
24. R.Bissonnette, T.Luger, D.Thaçi, et al. Secukinumab maintains high levels of efficacy through 3 years of treatment:results from an extension to a phase 3 study (SCULPTURE). Presented at the 24th Annual Congress of the European Academy of Dermatology and Venereology; 2015 Oct 7–11; Copenhagen, Denmark.
25. J.Harris, J.Keane. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1–9.
26. C.Pouplard, E.Brenaut, C.Horreau, et al. Risk of cancer in psoriasis:a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36–46.
27. E.J.Armstrong, C.T.Harskamp, A.W.Armstrong. Psoriasis and major adverse cardiovascular events:a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.
28. A.B.Gottlieb, R.Bissonnette, F.Kerdel, et al. Major adverse cardiovascular events in the Psoriasis Longitudial Assessment and Registry Study (PSOLAR):current status of observations [abstract]. J Am Acad Dermatol. 2015;75(5Suppl 1):AB240. Abstract 1956.
29. A.D.Cohen, J.Dreiher, S.Birkenfeld. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23:561–565.
30. W.Hueber, B.E.Sands, S.Lewitzky, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease:unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700.
31. S.K.Kurd, A.B.Troxel, P.Crits-Christoph, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis:a population-based cohort study. Arch Dermatol. 2010;146:891–895.
32. M.Lebwohl, B.Sherif, P.Mollon, et al. Secukinumab relieves pain and anxiety in psoriasis:results of two phase 3 trials. Presented at the 24th Annual Congress of the European Academy of Dermatology and Venereology; 2015 Oct 7–11; Copenhagen, Denmark.
33. J.H.Saurat, G.Stingl, L.Dubertret, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
34. A.Blauvelt, A.W.Armstrong, G.G.Krueger. Essential truths for the care and management of moderate-to-severe psoriasis. J Drugs Dermatol. 2015;14:805–812.
35. I.B.McInnes, P.J.Mease, B.Kirkham, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.• Pivotal study in the drug development program.
36. P.J.Mease, I.B.McInnes, B.Kirkham, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.• Pivotal study in the drug development program.
37. D.Baeten, J.Sieper, J.Braun, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548.• Pivotal study in the drug development program.